Industry
Biotechnology
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Loading...
Open
7.81
Mkt cap
281M
Volume
654K
High
7.89
P/E Ratio
-2.45
52-wk high
18.75
Low
7.44
Div yield
N/A
52-wk low
7.44
Portfolio Pulse from
November 26, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:22 am
Portfolio Pulse from Avi Kapoor
September 17, 2024 | 12:37 pm
Portfolio Pulse from Avi Kapoor
September 16, 2024 | 12:44 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:42 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:40 am
Portfolio Pulse from Avi Kapoor
September 16, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 8:47 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.